Atrial Fibrillation, Chronic Kidney Disease
Conditions
Keywords
warfarin, aspirin
Brief summary
In this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.
Detailed description
randomised open labelled prospective study We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg daly. Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding: gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM codes) -\> Only the first event of each case will be used for the analysis
Interventions
DRUGwarfarin
anticoagulation
DRUGAspirin
antiplatelet
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease
Exclusion criteria
* HAS-BLED ≥30 * History of syncope or seizure within 1 year * History of major bleeding event within 6 months * BP\>180/100 * Abnormal prothrombin time * Hypersensitivity of aspirin or warfarin * Folstein mini mental state examination score \<26 * Taking or had taken other anticoagulants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Thromboembolic event | through study completion, an average of 1 year | Ischemis stroke and systemic thromboembolism |
Secondary
| Measure | Time frame |
|---|---|
| Major bleeding | through study completion, an average of 1 year |
Countries
South Korea
Outcome results
None listed